Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | PTPRA | P18433 | 1/20 | 0.56 |
| ▸ | IKBKB | O14920 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409619 | 0.85 | PTPRF (0.53) | PTPN1IKBKBMAPTALDH1A1POLB | |
| SCHEMBL6348871 | 0.84 | PTPN1 (0.56) | PTPN1PTPRAIKBKBMAPTPOLB | |
| SCHEMBL4379744 | 0.80 | PTPN1 (0.49) | PTPN1PTPRAIKBKBMAPTALDH1A1 | |
| SCHEMBL2276857 | 0.80 | PTPN1 (0.49) | PTPN1PTPRAIKBKBMAPTALDH1A1 | |
| SCHEMBL2176910 | 0.78 | PTPN1 (0.58) | PTPN1PTPRAIKBKBMAPTALDH1A1 | |
| SCHEMBL1144476 | 0.78 | IKBKB (0.77) | PTPN1PTPRAIKBKBMAPTALDH1A1 | |
| SCHEMBL4870380 | 0.78 | PTPN1 (0.58) | PTPN1PTPRAIKBKBMAPTALDH1A1 | |
| SCHEMBL17226318 | 0.74 | PTPN1 (0.70) | PTPN1PTPRAIKBKBMAPTALDH1A1 | |
| SCHEMBL2169644 | 0.74 | PTPN1 (0.55) | PTPN1PTPRAIKBKBMAPTALDH1A1 | |
| SCHEMBL4194300 | 0.73 | PTPN1 (0.53) | PTPN1PTPRAIKBKBMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723331-B2 | Thienopyrimidine compounds and uses thereof | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-7723331-B2 | Thienopyrimidine compounds and uses thereof | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-7723331-B2 | Thienopyrimidine compounds and uses thereof | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| EP-2121703-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| CN-101528751-A | Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as MCH Rl antagonists | ASTRAZENECA AB (SE) | 2009-09-09 | — | — | CN | disclosed |
| US-20080221107-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| EP-1907398-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-09 | — | — | EP | disclosed |
| US-20080051405-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051405-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051405-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| WO-2008020799-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020799-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007011284-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051405-A1 | Therapeutic Agents | GPR119, HTT, IAPP | PTPN1 4648/4885PTPRA 3115/4885IKBKB 1388/4885 |
| US-20080221107-A1 | Therapeutic Agents | HTT, ACHE, GRIN2A | PTPN1 4747/4885PTPRA 3315/4885IKBKB 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.